Biomarkers, Subtyping Help Guide Neoadjuvant/Adjuvant Breast Cancer Treatment DecisionsJuly 8th 2016
For patients with early-stage invasive breast cancer and known estrogen receptor, progesterone receptor, and HER2 status, ASCO's February 2016 release of their evidence-based recommendations helped define appropriate use of biomarker assay results in guiding adjuvant treatment decisions.
Introduction to the Society for Immunotherapy of CancerJuly 5th 2016
The Society for Immunotherapy of Cancer (SITC) is the world's leading member-driven organization dedicated to professionals working in the field of cancer immunotherapy. A 501(c)(3) non-profit organization, SITC was established in 1984 to advance the science, development, and application of tumor immunology and cancer immunotherapy. SITC aims to make cancer immunotherapy a standard of care and the word "cure" a reality.
NCCN Tweaks Breast Cancer RecommendationsJuly 5th 2016
A number of small changes that were specific to neoadjuvant and adjuvant therapies were made to the NCCN breast cancer guidelines, additionally, the recommended treatments for patients with ER-positive disease were also modified.
Evidence for Selective Internal Radiation Therapy Continues to Emerge for Liver TumorsJuly 1st 2016
The treatment of colorectal cancer (CRC) has remained a significant clinical challenge, since over 50% of patients present with or develop liver metastases, which is a leading cause of death; however, a recent phase III study showed promise for selective internal radiation therapy (SIRT) in combination with standard chemotherapy as a first-line treatment.
Beyond PD-1/CTLA-4: Immunotherapy Combos Explore New GroundJune 28th 2016
A variety of dual immunotherapy combination regimens are currently under exploration that could build upon the success seen with the addition of the CTLA-4 inhibitor ipilimumab (Yervoy) to PD-1 blockade with nivolumab (Opdivo) for the treatment of patients with advanced melanoma.